Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

• US 10,233,244 B2
• Filed: 05/04/2016
• Issued: 03/19/2019
• Est. Priority Date: 05/04/2015
• Status: Active Grant

• Current Assignee: CytomX Therapeutics, Inc
• Original Assignee: CytomX Therapeutics, Inc
• Inventors: Sagert, Jason Gary, Terrett, Jonathan Alexander, Desnoyers, Luc Roland, Singh, Shweta, Weaver, Annie Yang
• Primary Examiner(s): Haddad, Maher M
• Application Number:
  US15/146,868
• Publication Number:
  US 20160355592A1
• Time in Patent Office: 1,049 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6803 Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• CPC Class Codes: A61K 47/6809 Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2839 against the integrin superfamily
• CPC Class Codes: C07K 16/2842 against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/50 containing protease site
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Claims

1. An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3, wherein the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO:

13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), and wherein the AB is humanized.

2. The AB of claim 1, wherein the AB comprises:

(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), or

(ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO;

10, and a light chain variable region comprising the amino acid sequence of SEQ ID NO;

11.

3. The AB of claim 1, wherein the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11 and 12.

4. An activatable antibody that, in an activated state, binds ITGa3 comprising:

an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3, wherein the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), and wherein the AB is humanized;

a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state; and

a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.

5. The activatable antibody of claim 4, wherein the MM has one or more of the characteristics selected from the group consisting of:

(i) the MM has a dissociation constant for binding to the AB that is greater than the dissociation constant of the AB to ITGa3;

(ii) the MM does not interfere or compete with the AB for binding to ITGa3 when the activatable antibody is in a cleaved state;

(iii) the MM is a polypeptide of no more than 40 amino acids in length;

(iv) the MM polypeptide sequence is different from that of human ITGa3;

(v) the MM polypeptide sequence is no more than 50% identical to any natural binding partner of the AB; and

(vi) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;

22-54.

6. The activatable antibody of claim 4, wherein

the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

182-249 and 276-316.

7. The activatable antibody of claim 4, wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab′

)₂ fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

8. The activatable antibody of claim 4, wherein the AB has one or more of the characteristics selected from the group consisting of:

(i) the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21); and

the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11 and 12.

9. The activatable antibody of claim 4, wherein the AB is linked to the CM.

10. The activatable antibody of claim 4, wherein the AB is linked directly to the CM.

11. The activatable antibody of claim 4, wherein the AB is linked to the CM via a linking peptide.

12. The activatable antibody of claim 4, wherein the MM is linked to the CM such that the activatable antibody in an uncleaved state comprises the structural arrangement from N-terminus to C-terminus as follows:

MM-CM-AB or AB-CM-MM.

13. The activatable antibody of claim 4, wherein the activatable antibody comprises a linking peptide between the MM and the CM, a linking peptide between the CM and the AB, or both a linking peptide between the MM and the CM and a linking peptide between the CM and the AB.

14. The activatable antibody of claim 4, wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2), and wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows:

MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM.

15. The activatable antibody of claim 14, wherein the two linking peptides are not identical to each other.

16. The activatable antibody of claim 14, wherein each of LP1 and LP2 is a peptide of about 1 to 20 amino acids in length.

17. The activatable antibody of claim 4, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:

(a) the activatable antibody comprises the heavy chain sequence of SEQ ID NO;

320 and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;

(b) the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,

(i) the heavy chain of the AB comprises a VH sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10 or a set of VH CDR sequences selected from the group consisting of SEQ ID NOs;

13, 15, and 18;

SEQ ID NOs;

13, 16, and 18; and

SEQ ID NOs;

13, 17, and 18,

(ii) the light chain of the AB comprises the VL sequence selected from the group consisting of SEQ ID NOs;

11 and 12 or the VL CDR sequences of SEQ ID NOs;

19, 20, and 21,

(iii) the MM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs;

22-54, and

(iv) the CM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs;

182-249 and 276-316; and

(c) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471.

19. A conjugated activatable antibody comprising the activatable antibody of claim 4 conjugated to an agent.

20. The conjugated activatable antibody of claim 19, wherein the agent has one or more of the characteristics selected from the group consisting of:

(a) the agent is a toxin or fragment thereof;

(b) the agent is a microtubule inhibitor;

(c) the agent is a nucleic acid damaging agent;

(d) the agent is a dolastatin or a derivative thereof;

(e) the agent is an auristatin or a derivative thereof;

(f) the agent is a maytansinoid or a derivative thereof;

(g) the agent is a duocarmycin or a derivative thereof;

(h) the agent is a calicheamicin or a derivative thereof;

(i) the agent is a pyrrolobenzodiazepine or a derivative thereof;

(j) the agent is auristatin E or a derivative thereof;

(k) the agent is monomethyl auristatin E (MMAE);

(l) the agent is monomethyl auristatin D (MMAD);

(m) the agent is the maytansinoid DM1;

(n) the agent is the maytansinoid DM4;

(o) the agent is a detectable moiety; and

(p) the agent is a diagnostic agent.

21. The conjugated activatable antibody of claim 19, wherein the agent is conjugated to the AB via a linker.

22. The conjugated activatable antibody of claim 21, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

23. The conjugated activatable antibody of claim 19, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of:

an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.

24. The conjugated activatable antibody of claim 21, wherein the linker is a cleavable linker.

25. The conjugated activatable antibody of claim 21, wherein the linker is a non-cleavable linker.

41. A pharmaceutical composition comprising the activatable antibody of claim 4 and a carrier.

42. The pharmaceutical composition of claim 41 comprising an additional agent.

43. The pharmaceutical composition of claim 42, wherein the additional agent is a therapeutic agent.

44. A pharmaceutical composition comprising the conjugated activatable antibody of claim 19;

and a carrier.

45. The pharmaceutical composition of claim 44 comprising an additional agent.

46. The activatable antibody of claim 4, wherein the MM is linked to the CM.

47. The activatable antibody of claim 4, wherein the MM is linked directly to the CM.

48. The activatable antibody of claim 4, wherein the MM is linked to the CM via a linking peptide.

18. An activatable antibody comprising an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, a masking moiety (MM), and a cleavable moiety (CM), wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:

(i) the activatable antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO;

320; and

a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;

(ii) the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21);

(iii) the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11 and 12; and

(iv) the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;

22-54, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs;

182-249 and 276-316.

26. A conjugated activatable antibody that, in an activated state, binds ITGa3 comprising:

(a) an activatable antibody comprising;

(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3, wherein the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), and wherein the AB is humanized;

(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state; and

(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and

(b) an agent conjugated to the AB.

27. The conjugated activatable antibody of claim 26, wherein the agent is selected from the group consisting of a dolastatin or a derivative thereof, an auristatin or a derivative thereof, a maytansinoid or a derivative thereof, a duocarmycin or a derivative thereof, a calicheamicin or a derivative thereof, a pyrrolobenzodiazepine or a derivative thereof, auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a duocarmycin, a calicheamicin, a pyrrolobenzodiazepine, and a pyrrolobenzodiazepine dimer.

28. The conjugated activatable antibody of claim 26, wherein the agent is conjugated to the AB via a linker.

29. The conjugated activatable antibody of claim 28, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

30. The conjugated activatable antibody of claim 26, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of:

an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.

31. The conjugated activatable antibody of claim 26, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:

(i) the activatable antibody comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21);

(ii) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471; and

(iii) the activatable antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO;

320; and

a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391.

32. The conjugated activatable antibody of claim 26, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

22-54.

33. The conjugated activatable antibody of claim 26, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

182-249 and 276-316.

34. The conjugated activatable antibody of claim 26, wherein

the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,

(i) the heavy chain of the AB comprises a VH sequence selected from the group consisting of SEQ ID NOs:

4-6 and 8-10 or a set of VH CDR sequences selected from the group consisting of SEQ ID NOs;

13, 15, and 18;

SEQ ID NOs;

13, 16, and 18; and

SEQ ID NOs;

13, 17, and 18,

(ii) the light chain of the AB comprises the VL sequence selected from the group consisting of SEQ ID NOs;

11 and 12 or the VL CDR sequences of SEQ ID NOs;

19, 20, and 21,

(iii) the MM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs;

22-54, and

(iv) the CM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs;

182-249 and 276-316.

35. A conjugated antibody comprising:

(a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB comprises;

(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), or

(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11 and 12;

or

(iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO;

320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO;

322; and

(b) an agent conjugated to the AB, wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

36. A conjugated activatable antibody that, in an activated state, binds to ITGa3, comprising:

(a) an activatable antibody comprising;

(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;

(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state;

(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and

(b) an agent conjugated to the AB,

wherein the activatable antibody comprises;

(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO;

     13);

a VH CDR2 comprising the amino acid sequence WFYPESGSVKYSETFKG (SEQ ID NO;

     15) or WFYPESGSVKYNEAFKG (SEQ ID NO;

     16) or WFYPESGSVKYNEGFKG (SEQ ID NO;

     17);

a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO;

     18);

a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO;

     19);

a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO;

     20); and

a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO;

     21), or

(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

4-6 and 8-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs;

11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471;

or

(iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO;

320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS;

255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391; and

wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

37. The conjugated activatable antibody of claim 36, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

22-54.

38. The conjugated activatable antibody of claim 36, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

182-249 and 276-316.

39. The conjugated activatable antibody of claim 36, wherein the agent is conjugated to the AB via a linker, and wherein the linker to which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

40. The conjugated antibody or conjugated activatable antibody of claim 36, wherein the linker and toxin conjugated to the AB comprises an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.